Previous Close | 1.0600 |
Open | 1.1000 |
Bid | 0.0000 x 1300 |
Ask | 0.0000 x 800 |
Day's Range | 1.1000 - 1.2900 |
52 Week Range | 0.8800 - 7.7200 |
Volume | |
Avg. Volume | 125,958 |
Market Cap | 17.567M |
Beta (5Y Monthly) | 0.23 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.9530 |
Earnings Date | Mar 28, 2022 - Apr 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of 13.73% and 40.65%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2022.
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported financial and corporate results for its fourth quarter and year ended December 31, 2021.